MENU
+Compare
AAVXF
Stock ticker: OTC
AS OF
Aug 7 closing price
Price
$71.00
Change
-$0.02 (-0.03%)
Capitalization
5.33B

AAVXF stock forecast, quote, news & analysis

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases... Show more

AAVXF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period.
Interact to see
Advertisement
A.I.Advisor
a Summary for AAVXF with price predictions
Aug 08, 2025

AAVXF saw its Stochastic Oscillator leaves the overbought zone

The Stochastic Oscillator for AAVXF moved out of overbought territory on August 07, 2025. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 25 similar instances where the indicator exited the overbought zone. In of the 25 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis
Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for AAVXF just turned positive on July 21, 2025. Looking at past instances where AAVXF's MACD turned positive, the stock continued to rise in of 20 cases over the following month. The odds of a continued upward trend are .

The 50-day moving average for AAVXF moved above the 200-day moving average on July 24, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AAVXF advanced for three days, in of 8 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 107 cases where AAVXF Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AAVXF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock slightly better than average.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.006) is normal, around the industry mean (18.662). P/E Ratio (0.000) is within average values for comparable stocks, (54.033). AAVXF's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.909). Dividend Yield (0.000) settles around the average of (0.049) among similar stocks. P/S Ratio (140.845) is also within normal values, averaging (286.048).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Moderna (NASDAQ:MRNA), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 1.78B. The market cap for tickers in the group ranges from 31.65 to 93.98B. VRTX holds the highest valuation in this group at 93.98B. The lowest valued company is CYCCP at 31.65.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 22%. For the same Industry, the average monthly price growth was 31%, and the average quarterly price growth was 20%. SPRBD experienced the highest price growth at 9,061%, while BIVI experienced the biggest fall at -72%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -26%. For the same stocks of the Industry, the average monthly volume growth was -59% and the average quarterly volume growth was 87%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 84
Price Growth Rating: 59
SMR Rating: 93
Profit Risk Rating: 95
Seasonality Score: -14 (-100 ... +100)
View a ticker or compare two or three
AAVXF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
7-11 boulevard Haussmann
Phone
+33 153830963
Employees
24
Web
https://www.abivax.com